Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)

Figure 1: Trends in incident cases of PTCL, 2017–26
Figure 2: Incident cases of PTCL, by age, 2017
Figure 3: Overview of pipeline drugs for PTCL in the US
Figure 4: Pipeline drugs for PTCL, by company
Figure 5: Pipeline drugs for PTCL, by drug type
Figure 6: Pipeline drugs for PTCL, by classification
Figure 7: ALXN2075 for PTCL (December 8, 2019): Phase I/IIa - Two Part Dose Escalation
Figure 8: Key upcoming events in PTCL
Figure 9: Probability of success in the hematologic pipeline
Figure 10: Clinical trials in PTCL
Figure 11: Top 10 drugs for clinical trials in PTCL
Figure 12: Top 10 companies for clinical trials in PTCL
Figure 13: Trial locations in PTCL
Figure 14: PTCL trials status
Figure 15: PTCL trials sponsors, by phase

Table 1: Incident cases of PTCL, 2017–26
Table 2: Incident cases of PTCL, by gender, 2017
Table 3: Marketed drugs for PTCL
Table 4: Pipeline drugs for PTCL in the US
Table 5: ALXN2075 for PTCL (December 8, 2019)
Table 6: Tipifarnib (Oncology) for PTCL (December 8, 2019)
Table 7: Copiktra for PTCL (December 7, 2019)
Table 8: Historical global sales, by drug ($m), 2016–20
Table 9: Forecasted global sales, by drug ($m), 2021–25